Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA

Experimental Neurology

Volumn 230, Issue 1, 2011, Pages 123-130

  Rozaklis, Tina ^a   Beard, Helen ^a   Hassiotis, Sofia ^a   Garcia, Antony R ^b   Tonini, Matthew ^b   Luck, Amanda ^a   Pan, Jing ^b   Lamsa, Justin C ^b   Hopwood, John J ^a   Hemsley, Kim M ^a  

^a Lysosomal Diseases Research Unit   (Australia)

^b SHIRE   (United States)

Author keywords

Brain; Enzyme replacement therapy; Mouse; Mucopolysaccharidosis; Sanfilippo

Indexed keywords

SULFATASE; SULPHOGLUCOSAMINE SULPHOHYDROLASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CHOROID PLEXUS; CONTROLLED STUDY; CYTOCHEMISTRY; DISEASE MODEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG LIVER LEVEL; DRUG MEGADOSE; DRUG TISSUE LEVEL; ENDOTHELIUM; ENZYME REPLACEMENT; IMMUNOHISTOCHEMISTRY; MENINX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SANFILIPPO SYNDROME;

ANIMALS; BRAIN; CHOROID PLEXUS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYDROLASES; MANNOSEPHOSPHATES; MENINGES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUCOPOLYSACCHARIDOSIS III; OLIGORIBONUCLEOTIDES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TIME FACTORS;

EID: 79958024590     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.04.004     Document Type: Article

References (30)

1. Barton N.W., Furbish F.S., Murray G.J., Garfield M., Brady R.O. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc. Natl Acad. Sci. U S A 1990, 87:1913-1916.
2. Bhaumik M., Muller V.J., Rozaklis T., Johnson L., Dobrenis K., Bhattacharyya R., Wurzelmann S., Finamore P., Hopwood J.J., Walkley S.U., Stanley P. A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 1999, 9:1389-1396.
3. Bielicki J., Hopwood J.J., Melville E.L., Anson D.S. Recombinant human sulphamidase-expression, amplification, purification and characterization. Biochem. J. 1998, 329:145-150.
4. Blanz J., Stroobants S., Lullmann-Rauch R., Morelle W., Ludemann M., D'Hooge R., Reuterwall H., Michalski J.C., Fogh J., Andersson C., Saftig P. Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice. Hum. Mol. Genet. 2008, 17:3437-3445.
5. Crawley A.C., King B., Berg T., Meikle P.J., Hopwood J.J. Enzyme replacement therapy in alpha-mannosidosis guinea-pigs. Mol. Genet. Metab. 2006, 89:48-57.
6. Crawley A.C., Gliddon B.L., Auclair D., Brodie S.L., Hirte C., King B.M., Fuller M., Hemsley K.M., Hopwood J.J. Characterization of a C57BL/6 congenicmouse strain of mucopolysaccharidosis type IIIA. Brain Res. 2006, 1104:1-17.
7. Dunder U., Kaartinen V., Valtonen P., Vaananen E., Kosma V.M., Heisterkamp N., Groffen J., Mononen I. Enzyme replacement therapy in a mouse model of aspartylglycosaminuria. FASEB J. 2000, 14:361-367.
8. Garbuzova-Davis S., Louis M.K., Haller E.M., Derasari H.M., Rawls A.E., Sanberg P.R. Blood-brain barrier impairment in an animal model of MPS IIIB. PLoS One 2011, 6(3):216601. 10.1371/journal.pone.0016601.
9. Gliddon B.L., Hopwood J.J. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice. Pediatr. Res. 2004, 56:65-72.
10. Grubb J.H., Vogler C., Levy B., Galvin N., Tan Y., Sly W.S. Chemically modified {beta}-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII. Proc. Natl Acad. Sci. USA 2008, 105:2616-2621.
11. Harmatz P., Giugliani R., Schwartz I., Guffon N., Teles E.L., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Yu Z.F., Wittes J., Berger K.I., Newman M.S., Lowe A.M., Kakkis E., Swiedler S.J. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J. Pediatr. 2006, 148:533-539.
12. Hemsley K.M., King B., Hopwood J.J. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. Mol. Genet. Metab. 2007, 90:313-328.
13. Hemsley K.M., Luck A.J., Crawley A.C., Hassiotis S., Beard H., King B., Rozek T., Rozaklis T., Fuller M., Hopwood J.J. Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease. Eur. J. Neurosci. 2009, 29:1197-1214.
14. Hopwood J.J., Elliott H. Diagnosis of Sanfilippo type A syndrome by estimation of sulfamidase activity using a radiolabelled tetrasaccharide substrate. Clin. Chim. Acta. 1982, 123:241-250.
15. Hopwood J.J., Morris C.P. The mucopolysaccharidoses. Diagnosis, molecular genetics and treatment. Mol. Biol. Med. 1990, 7:381-404.
16. Kakkis E.D., Muenzer J., Tiller G.E., Waber L., Belmont J., Passage M., Izykowski B., Phillips J., Doroshow R., Walot I., Hoft R., Neufeld E.F. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 2001, 344:182-188.
17. Lau A.A., Hopwood J.J., Kremer E.J., Hemsley K.M. SGSH gene transfer in mucopolysaccharidosis type IIIA mice using canine adenovirus vectors. Molec. Genet. Metab. 2010, 100:168-175.
18. Lau A.A., Hannouche H., Rozaklis T., Hassiotis S., Hopwood J.J., Hemsley K.M. Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type iiia mice. Exp. Neurol. 2010, 225:445-454.
19. Lee W.C., Courtenay A., Troendle F.J., Stallings-Mann M.L., Dickey C.A., DeLucia M.W., Dickson D.W., Eckman C.B. Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy. FASEB J. 2005, 19:1549-1551.
20. Matzner U., Lullmann-Rauch R., Stroobants S., Andersson C., Weigelt C., Eistrup C., Fogh J., D'Hooge R., Gieselmann V. Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy. Mol. Ther. 2009, 17:600-606.
21. McGlynn R., Dobrenis K., Walkley S.U. Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J. Comp. Neurol. 2004, 480:415-426.
22. Muenzer J., Lamsa J.C., Garcia A., Dacosta J., Garcia J., Treco D.A. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr. Suppl. 2002, 91:98-99.
23. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego, CA.
24. Polito V.A., Abbondante S., Polishchuk R.S., Nusco E., Salvia R., Cosma M.P. Correction of CNS defects in the MPS II mouse model via systemic enzyme replacement therapy. Hum. Mol. Genet. 2010, 19:4871-4885.
25. Roces D.P., Lullmann-Rauch R., Peng J., Balducci C., Andersson C., Tollersrud O., Fogh J., Orlacchio A., Beccari T., Saftig P., von Figura K. Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: a preclinical animal study. Hum. Mol. Genet. 2004, 13:1979-1988.
26. Schiffmann R., Kopp J.B., Austin H.A.r., Sabnis S., Moore D.F., Weibel T., Balow J.E., Brady R.O. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001, 285:2743-2749.
27. Scott H.S., Blanch L., Guo X.-H., Freeman V.C., Orsborn A., Baker E., Sutherland G.R., Morris P., Hopwood J.J. Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome. Nat. Genet. 1995, 11:465-467.
28. Tsai P.S., Kaufhold J.P., Blinder P., Friedman B., Drew P.J., Karten H.J., Lyden P.D., Kleinfeld D. Correlations of neuronal and microvascular densities in murine cortex revealed by direct counting and colocalization of nuclei and vessels. J. Neurosci. 2009, 29:14553-14570.
29. Urayama A., Grubb J.H., Sly W.S., Banks W.A. Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse. Mol. Ther. 2008, 16:1261-1266.
30. Vogler C., Levy B., Grubb J.H., Galvin N., Tan Y., Kakkis E., Pavloff N., Sly W.S. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc. Natl Acad. Sci. USA 2005, 102:14777-14782.